论文部分内容阅读
利培酮长效注射液(RLAI)是第一个非典型抗精神病药长效剂型,由美国杨森公司开发,于2003年在欧美上市,2006年进入我国市场。它采用微球体(Medisorb)技术改为注射剂,避开了肝首过效应,提高了生物利用度;具有在体内缓慢均匀释放的特性,能使血药浓度保持较长时间稳定;与传统的长效剂型和母体药利培酮相比,RLAI在药理上有很多不同处,且具有临床药效好、不良反应少、安全性较高,患者的依从性较好,有较好的“成本-疗效比”效益等优势。现根据文献将RLAI的药理与临床研究概况作一综述。
Risperidone long-acting injection (RLAI) is the first atypical antipsychotic long-acting formulations, developed by the United States Janssen company, in Europe and the United States in 2003 listed in 2006 to enter the Chinese market. It uses the microsphere (Medisorb) technology into injection, to avoid the first pass of the liver effect and improve the bioavailability; with slow release in the body of the characteristics of the blood concentration can make a long time stability; with the traditional long Compared with the parent drug risperidone, RLAI has many pharmacological differences and has good clinical efficacy, less adverse reactions, higher safety, better patient compliance and better “cost” - Efficacy than “” benefits and other advantages. Now based on the literature RLAL pharmacological and clinical research to make a summary.